A Phase 2 interventional study of Duloxetine and Sugar pill in Traumatic Brain Injury and Depression, sponsored by Rehabilitation Hospital of Indiana. Terminated at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-12-17.
Sponsored by Rehabilitation Hospital of Indiana · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 909 studies in Brain Injuries, Traumatic with a site in United States — 212 open to participants now, 250 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.
Among the 909 studies in Brain Injuries, Traumatic with a site in United States, this one is the 576th largest by enrollment of the 650 interventional ones that give a count, is the only one that started in 1996, is one of 78 in phase 2, and was the 145th registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →212 of the 909 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:
Shirley Ryan AbilityLab · Sites in United States
Ages 18–75
Andrew Mayer · Sites in United States
Ages 18–82 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–55
Columbia University · Sites in United States
Ages 18+
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
909 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 110 · Phase 3 39 · Phase 4 28
First in 1996; this study’s year is marked. 1 started in 1996.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 50 across the 650 interventional studies, 120 across the 257 observational. Of the 553 that completed or were terminated, 182 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 909 have an industry lead sponsor. The 10 most frequent:
Rehabilitation Hospital of Indiana is the lead sponsor of 6 studies on the registry; none are open to participants now.
Rehabilitation Hospital of Indiana has 5 studies filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
83 of the studies in Brain Injuries, Traumatic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06368648CoMind Technologies LimitedCoMind Early Feasibility Study | 2026-11 |
| NCT06103201University of Maryland, BaltimoreHyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury | 2026-11-26 |
| NCT07733284Kessler FoundationHome-Based Walking for Thinking Skills in Persons With TBI | 2026-12 |
| NCT06228391Minneapolis Veterans Affairs Medical CenterKetamine Treatment for PTSD and MDD in TBI | 2026-12 |
| NCT05702138Craig HospitalHigh Intensity Step Training After Traumatic Brain Injury | 2026-12 |
Add all 83 to your calendar (.ics) → With an account.
Among the 909 studies in Brain Injuries, Traumatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to compare the efficacy of duloxetine 60 mg by mouth daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury and to enhance cognitive function.
The primary objective of the study is to compare the efficacy of duloxetine 60 mg by mouth daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury and to enhance cognitive function. Research exploring the use of selective serotonin reuptake inhibitors in the treatment of post-traumatic depression generally validates this approach (Horsfield et al., 2002). However, the literature suggests that serotonin/norepinephrine reuptake inhibitors such as duloxetine may be more effective in the treatment of depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Drug: Duloxetine
Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Drug: Sugar pill
Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Also known as: Cymbalta
Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Also known as: Lactose
Hamilton Rating Scale for Depression
To compare the efficacy of duloxetine 30 mg. PO daily to 120mg. PO daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury, utilizing the Hamilton Rating Scale for Depression (Hamilton, 1960; HAM-D) as the primary efficacy measure.
Time frame: 9 months
Hopkins Verbal Learning Test
To compare the effect of duloxetine vs. placebo on the recovery of memory functions of patients with traumatic brain injury, utilizing the 20-minute delayed recall score of the Hopkins Verbal Learning Test (Brandt, 1991) as the secondary efficacy measure.
Time frame: 9 months
Subjects recruited from in-patient and medical clinic population. All subjects suffering from traumatic brain injury and loss of cognitive function.
| Milestone | Duloxetine | Sugar Pill |
|---|---|---|
| Started | 4 | 4 |
| Completed | 0 | 0 |
| Not completed | 4 | 4 |
To compare the efficacy of duloxetine 30 mg. PO daily to 120mg. PO daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury, utilizing the Hamilton Rating Scale for Depression (Hamilton, 1960; HAM-D) as the primary efficacy measure.
No measurements were reported for this outcome.
To compare the effect of duloxetine vs. placebo on the recovery of memory functions of patients with traumatic brain injury, utilizing the 20-minute delayed recall score of the Hopkins Verbal Learning Test (Brandt, 1991) as the secondary efficacy measure.
Results for this outcome have not been posted.
Collected over Duration of study participation per subject.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Duloxetine | — | 0/4 (0%) | 0/4 (0%) |
| Sugar Pill | — | 0/4 (0%) | 0/4 (0%) |
| Age, Categorical(Participants) | Duloxetine | Sugar Pill | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 4 | 8 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Duloxetine | Sugar Pill | Total |
|---|---|---|---|
| Female | 0 | 1 | 1 |
| Male | 4 | 3 | 7 |
| Region of Enrollment(participants) | Duloxetine | Sugar Pill | Total |
|---|---|---|---|
| United States | 4 | 4 | 8 |
The record gives a start of Sep 1996, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Duloxetine
Rehabilitation Hospital of Indiana